Biopartners GmbH and LG Life Sciences Ltd (LGLS) Present Positive Phase 3, Twenty-Four Months Efficacy and Safety Data for Sustained Release Recombinant Human Growth Hormone (LB03002) Given to Children with Growth Hormone Deficiency
Biopartners GmbH and LG Life Sciences Ltd (LGLS) today presented positive Phase 3 results of 24 months efficacy and safety in children with growth hormone deficiency (GHD) for LB03002, a once-a-week, sustained release recombinant human growth hormone (hGH), at the 50th annual meeting of the European Society for Paediatric Endocrinology (ESPE 2011) in Glasgow, Scotland.
A Phase 3 trial conducted globally, including Europe and the US, involving 167 paediatric patients with GHD demonstrated that LB03002, using LGLS’ proprietary delivery technology Biohydrix® , maintained expected growth rates for patients continuously treated for 24 months as well as in patients treated for 12 months who were switched from daily therapy. IGF-1 levels continued to increase toward the normal range in both groups during LB03002 treatment, a key marker of efficacy and safety in growth hormone therapy. LB03002 was well tolerated and demonstrated a sustained growth potential without excessive bone maturation.
Commenting on these new results Dr. Conrad Savoy, CEO of Biopartners GmbH said, “We are truly excited about the positive impact of this innovative once-a-week recombinant human growth hormone. These positive data further confirm previously presented positive data in children with GHD from a two year comparative trial versus daily growth hormone which was followed by a one year extension."
Dr. Hyi-Jeong Ji, VP of hGH Development at LGLS commented, “Based on this comprehensive set of data in GHD children together with 12 months of efficacy and safety in GHD adults, we believe this novel once-a-week hGH will offer a very attractive treatment modality to endocrinologists and their patients, leading to better adherence to long-term therapy, and ultimately, a more successful treatment outcome.”
LB03002 was originally developed by LGLS who granted Biopartners a license to further develop and market the product in Europe, Australia, New-Zealand and several other countries. LGLS retains rights in the rest of the world including North and South America, and most Asian countries including Korea, Japan, and China. An extension of this paediatric Phase 3 study is currently ongoing in India and Egypt.
About BioHydrix®
BioHydrix® is an LGLS proprietary sustained release (SR) technology with significant potential in the delivery of biologics. The unique hyaluronan microparticle matrix enables extended release of active substance.
About Biopartners
Established in 2000, Biopartners' aim is to be a leader in developing and commercializing innovative formulations and novel delivery systems of first-generation biopharmaceuticals for which there are substantial unmet medical/patients' needs.
Biopartners seeks to offer safe and efficacious biopharmaceutical therapies. Its product portfolio covers the fields of endocrinology, multiple sclerosis and virology.
With its head office located in Switzerland, and an affiliate located in Germany, Biopartners is building an international network through a series of collaborations and partnerships. For more information, please visit the company’s website at: www.biopartners.ch .
About LG Life Science
LG Life Sciences, Ltd. is the leading Korean pharmaceutical company based in Seoul, Korea, committed to promoting the health and well-being of patients. The company’s key therapeutic areas include metabolic and cardiovascular diseases as well as infectious and liver diseases. LGLS seeks to continue developing global brand products such as Factive® (gemifloxacin) and expanding its marketing presence across the globe. For more information, please visit the company’s website at: www.lgls.com .
Contact:
Biopartners GmbH
Dr Conrad Savoy
E-mail: Conrad@biopartners.ch
Tel:
+41 41 766 2080
LG Life Sciences, Ltd.
Junhyung Park
E-mail:
chunjae@lgls.com
Tel: +82 2
6924 3366
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Microba Delivers Landmark IBD Results & Signs Major Gastro Partner29.4.2025 07:52:00 CEST | Press release
Two independent clinical studies have demonstrated that Microba’s MetaPanel™ test identifies gastrointestinal pathogens in >35% of Inflammatory Bowel Disease (IBD) patients experiencing flare, with >60% of these missed by current routine testing methods.These findings have the potential to shift treatment protocols and provide a new path to remission for IBD patients, avoiding unnecessary therapy escalation or surgery.Microba partners with Colonoscopy Clinic and Integrated Gut Health, one of Australia’s largest private gastroenterology services, to embed microbial diagnostic testing into routine care to improve patient outcomes. Microba Life Sciences Limited (ASX: MAP) (“Microba”) a precision microbiome company, today announces two significant developments: the release of new clinical utility results for its MetaPanel™ gastrointestinal pathogen test, and the signing of a strategic clinical partnership with the Colonoscopy Clinic, and its wholly owned partner, Integrated Gut Health, one
VeriSilicon Launches the Industry-Leading Automotive-Grade Intelligent Driving SoC Design Platform29.4.2025 02:00:00 CEST | Press release
Providing one-stop custom service from chip design and verification to automotive-grade certification VeriSilicon (688521.SH) recently announced that its automotive-grade high-performance intelligent driving system-on-chip (SoC) design platform has been verified and successfully implemented in customer projects. Leveraging VeriSilicon’s Silicon Platform as a Service (SiPaaS) business model, this platform provides robust technical support for high-performance computing applications such as autonomous driving and advanced driver assistance systems (ADAS). VeriSilicon’s chip design process has obtained ISO 26262 automotive functional safety management system certification, enabling the company to provide global customers with one-stop custom service for their automotive chips that meet functional safety requirements. Combined with its extensive portfolio of automotive-grade IPs and complete intelligent driving software platform, VeriSilicon offers end-to-end support from chip design and v
IFF Pharma Solutions to Showcase Portfolio at Excipient World 202528.4.2025 23:00:00 CEST | Press release
Sustainability Expert Will Share Key Insights on Industry-Leading Solutions for Improving Environmental Impact IFF (NYSE: IFF) Pharma Solutions, a global leader in polymer innovations, will showcase its sustainable solutions at Excipient World 2025. The team will feature sustainable innovations, controlled-release formulations, and nitrosamine risk mitigation solutions at booth 205 from May 13-14, Gaylord National Resort and Convention Center, National Harbor, Maryland, USA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428283122/en/ “At IFF Pharma Solutions, we believe sustainability is not just a responsibility but an opportunity to innovate and inspire,” said Dr. Anne Adden, global strategic marketing director for sustainability and dietary supplements. “We are committed to creating solutions that not only meet the needs of today but also pave the way for a healthier, more sustainable future. Our team of problem-solve
Winka Dubbeldam Appointed Director and CEO of SCI-Arc28.4.2025 20:50:00 CEST | Press release
The Southern California Institute of Architecture (SCI-Arc) is thrilled to share that Prof. Winka Dubbeldam has been appointed as the next Director and Chief Executive Officer of SCI-Arc. A globally recognized Dutch architect, educator, and leader in design innovation, Winka will officially assume the role on September 1, 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250428994100/en/ Winka Dubbeldam Winka brings more than three decades of experience to the forefront of architectural practice and education. She is a full Professor of Architecture and served as Chair at the University of Pennsylvania Stuart Weitzman School of Design for ten years (2013–2023). Previously she initiated and directed the Post-Professional Architecture program for ten years (2003–2013), providing international students with innovative design skills, cutting-edge theoretical and technological knowledge necessary for a productive and innovativ
NIQ announces global data collaboration with The Trade Desk to enhance audience targeting28.4.2025 19:37:00 CEST | Press release
The Trade Desk is the first global technology platform to integrate new-to-market audiences NIQ, a leading consumer intelligence company, today announced a strategic global collaboration with The Trade Desk, a global leader in advertising technology. The collaboration will integrate NIQ's consumer intelligence and global insights on shopping behaviors into The Trade Desk’s platform, supporting marketers to plan and activate ad campaigns more accurately. These new-to-market audiences, now available on The Trade Desk's media buying platform, will enable advertisers to reach their desired audiences in global markets, with effectiveness and precision. "Our collaboration with The Trade Desk represents a significant step forward in our mission to provide actionable insights across the advertising industry, at a global scale," said Joshua Pisano, Global Head of Product, Media at NIQ. "By integrating NIQ’s advanced audiences into The Trade Desk’s leading data marketplace, we are empowering adv
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom